Back to today’s briefing

Story perspectives

GLP-1 Medications Revolutionize Menopause Weight Management

10/4/2025

24 5

Summary

Story summary

Glucagon-like peptide-1 (GLP-1) medications, including Ozempic and Wegovy, are a leading option for menopause-weight gain.
The global menopause market is expected to grow from nearly $18 billion in 2024 to over $24 billion by 2030.
A trial found a plant-focused diet cut hot flashes by 92% and aided weight loss. Experts say GLP-1 receptor agonists are becoming first-line treatment.

1 of 1

Story summary

Glucagon-like peptide-1 (GLP-1) medications, including Ozempic and Wegovy, are a leading option for menopause-weight gain.
The global menopause market is expected to grow from nearly $18 billion in 2024 to over $24 billion by 2030.
A trial found a plant-focused diet cut hot flashes by 92% and aided weight loss. Experts say GLP-1 receptor agonists are becoming first-line treatment.